Solid lercanidipine free base
    2.
    发明申请
    Solid lercanidipine free base 审中-公开
    固体氯卡地平游离碱

    公开(公告)号:US20060199849A1

    公开(公告)日:2006-09-07

    申请号:US11364861

    申请日:2006-02-27

    IPC分类号: C07D211/82 A61K31/44

    CPC分类号: C07D211/90

    摘要: The invention provides substantially pure lercanidipine free base, having a purity of at least 95%, preferably at least 97%, more preferably at least 99%, and still more preferably at least 99.5%. The lercanidipine free base of the present invention is formed as an amorphous solid that is easily handled and particularly well suited to the formulation of pharmaceutical compositions.

    摘要翻译: 本发明提供基本上纯的氯卡地平碱,其纯度至少为95%,优选至少97%,更优选至少99%,还更优选至少99.5%。 本发明的氯卡地平游离碱形成为易于处理的非晶态固体,特别适用于药物组合物的制剂。

    Lercanidipine capsules
    3.
    发明申请
    Lercanidipine capsules 审中-公开
    Lercanidipine胶囊

    公开(公告)号:US20060073200A1

    公开(公告)日:2006-04-06

    申请号:US11244315

    申请日:2005-10-04

    IPC分类号: A61K31/455 A61K9/48

    摘要: The invention provides a modified release lercanidipine pharmaceutical composition comprising at least one waxy substance and a therapeutically effective amount of lercanidipine, wherein oral administration of the modified release lercanidipine pharmaceutical composition to a patient results in a mean lercanidipine plasma concentration of greater than 0.5 ng/ml for the full time period of about 24 hours after administration of the composition to the patient.

    摘要翻译: 本发明提供了包含至少一种蜡质物质和治疗有效量的氯卡地平的改良释放氯卡地平药物组合物,其中向患者口服给予改良释放的氯卡地平药物组合物导致平均lercanidipine血药浓度大于0.5ng / ml 在将组合物施用于患者后约24小时的全部时间段。

    Amorphous lercanidipine hydrochloride and uses thereof
    4.
    发明授权
    Amorphous lercanidipine hydrochloride and uses thereof 有权
    盐酸非卡那泊地平及其用途

    公开(公告)号:US07820701B2

    公开(公告)日:2010-10-26

    申请号:US11364862

    申请日:2006-02-27

    IPC分类号: C07D211/82 A61K31/455

    CPC分类号: C07D211/90

    摘要: The invention provides a substantially pure amorphous lercanidipine hydrochloride having a purity of at least 95% pure, preferably at least about 97% pure, more preferably at least about 99% pure, and still more preferably at least about 99.5% pure. The invention further relates to methods of preparing substantially pure amorphous lercanidipine, as well as methods of providing rapid relief from hypertension by administering the substantially pure amorphous lercanidipine hydrochloride of the present invention to a patient in need of such treatment.

    摘要翻译: 本发明提供纯度为纯度至少95%纯,优选至少约97%纯度,更优选至少约99%纯度,还更优选至少约99.5%纯度的基本上纯的无定形二卡尼平盐酸盐。 本发明还涉及制备基本上纯的无定形二卡尼地平的方法,以及通过向需要这种治疗的患者施用本发明的基本上纯的无定形伊卡尼地平盐酸盐来提供快速缓解高血压的方法。

    Amorphous lercanidipine hydrochloride and uses thereof
    5.
    发明申请
    Amorphous lercanidipine hydrochloride and uses thereof 有权
    盐酸非卡那泊地平及其用途

    公开(公告)号:US20060211742A1

    公开(公告)日:2006-09-21

    申请号:US11364862

    申请日:2006-02-27

    IPC分类号: A61K31/455 C07D211/82

    CPC分类号: C07D211/90

    摘要: The invention provides a substantially pure amorphous lercanidipine hydrochloride having a purity of at least 95% pure, preferably at least about 97% pure, more preferably at least about 99% pure, and still more preferably at least about 99.5% pure. The invention further relates to methods of preparing substantially pure amorphous lercanidipine, as well as methods of providing rapid relief from hypertension by administering the substantially pure amorphous lercanidipine hydrochloride of the present invention to a patient in need of such treatment.

    摘要翻译: 本发明提供纯度为纯度至少95%纯,优选至少约97%纯度,更优选至少约99%纯度,还更优选至少约99.5%纯度的基本上纯的无定形二卡尼平盐酸盐。 本发明还涉及制备基本上纯的无定形二卡尼地平的方法,以及通过向需要这种治疗的患者施用本发明的基本上纯的无定形伊卡尼地平盐酸盐来提供快速缓解高血压的方法。

    Transmucosal gel formulations
    6.
    发明申请
    Transmucosal gel formulations 审中-公开
    透粘胶凝胶制剂

    公开(公告)号:US20050260253A1

    公开(公告)日:2005-11-24

    申请号:US11134743

    申请日:2005-05-20

    摘要: This invention relates to pharmaceutical formulations for the transmucosal delivery of 4-amino-6,7-dimethoxy-2-{4-[(2-isopropyl-6-methoxyphenoxy)acetyl]-1-piperazinyl}quinazoline (Rec 15/2615), which has the formula: The formulations are useful in methods for enhancing the sexual act for females, including treatment of female sexual dysfunction.

    摘要翻译: 本发明涉及用于经粘膜递送4-氨基-6,7-二甲氧基-2- {4 - [(2-异丙基-6-甲氧基苯氧基)乙酰基] -1-哌嗪基}喹唑啉(Rec 15/2615)的药物制剂, 其具有以下公式:该制剂可用于增强女性性行为的方法,包括治疗女性性功能障碍。